Roche Holding (SWX:ROP) Licensed An ALK7 RNAi Obesity Therapy

Roche Holding (SWX:ROP) has agreed an exclusive global licence with Rona Therapeutics for an ALK7-targeting RNAi obesity therapy. The licensed RNA interference drug is designed to act in adipose tissue and aims to cut visceral fat while preserving lean mass. The collaboration extends Roche's presence in RNA based treatments for metabolic diseases by using Rona Therapeutics' RNAi platform. Roche's ALK7 RNAi licensing deal with Rona sits alongside other factors that shape the wider picture for...